Hepatitis B Core Antibody: Role in Clinical Practice in 2020

Purpose of Review It is crucial for clinicians to understand the need to screen for hepatitis B core antigen (anti-HBc status), proper interpretation of HBV biomarkers, and that “anti-HBc only” indicates HBV exposure, lifelong persistence of cccDNA with incomplete infection control, and potential ri...

Full description

Saved in:
Bibliographic Details
Published in:Current hepatology reports 2020-09, Vol.19 (3), p.254-265
Main Authors: Gish, Robert G., Basit, Syed Abdul, Ryan, John, Dawood, Altaf, Protzer, Ulrike
Format: Article
Language:English
Subjects:
Hepatitis B (JK Lim
Hepatology
Medicine
Medicine & Public Health
Section Editor
Topical Collection on Hepatitis B
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2500-2094ad901b956685bfcb2b828027227d559c212f7e3eba75c810c4face7b34dd3
cites cdi_FETCH-LOGICAL-c2500-2094ad901b956685bfcb2b828027227d559c212f7e3eba75c810c4face7b34dd3
container_end_page 265
container_issue 3
container_start_page 254
container_title Current hepatology reports
container_volume 19
creator Gish, Robert G.
Basit, Syed Abdul
Ryan, John
Dawood, Altaf
Protzer, Ulrike
description Purpose of Review It is crucial for clinicians to understand the need to screen for hepatitis B core antigen (anti-HBc status), proper interpretation of HBV biomarkers, and that “anti-HBc only” indicates HBV exposure, lifelong persistence of cccDNA with incomplete infection control, and potential risk for reactivation. Findings Many common misconceptions exist, including that tests for anti-HBc have high false-positive rates, that patients with anti-HBc alone or occult hepatitis B may profit from “vaccine boosting” to achieve immune control of HBV, and that anti-HBc(+)/anti-HBs(+) patients have cleared HBV when they have actually achieved immune control, while HBV persists in some hepatocytes and can reactivate. Summary This review breaks down several common misconceptions regarding anti-HBc with the most recent evidence. In addition, current best strategies for anti-HBc testing and interpretation are reviewed and summarized.
doi_str_mv 10.1007/s11901-020-00522-0
format article
fullrecord <record><control><sourceid>crossref_sprin</sourceid><recordid>TN_cdi_crossref_primary_10_1007_s11901_020_00522_0</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1007_s11901_020_00522_0</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2500-2094ad901b956685bfcb2b828027227d559c212f7e3eba75c810c4face7b34dd3</originalsourceid><addsrcrecordid>eNp9kMFKAzEQhoMoWGpfwFNeIDqZ3TQb8VIXtUKhRfQckmxWUtbdkqyHvr2x68GTpxmG-WZ-PkKuOdxwAHmbOFfAGSAwAIHI4IzMkCvBlFDi_E9_SRYp7QGAo5AS-Yzcr_3BjGEMiT7Qeoiervox2KE53tHXofM09LTuQh-c6eguGjcGdxpifndFLlrTJb_4rXPy_vT4Vq_ZZvv8Uq82zKEAYAiqNE2OaJVYLithW2fRVlgBSkTZCKEccmylL7w1UriKgytb47y0Rdk0xZzgdNfFIaXoW32I4dPEo-agfxToSYHOmfRJgYYMFROU8nL_4aPeD1-xzzn_o74BJrBbpQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Hepatitis B Core Antibody: Role in Clinical Practice in 2020</title><source>Springer Nature</source><creator>Gish, Robert G. ; Basit, Syed Abdul ; Ryan, John ; Dawood, Altaf ; Protzer, Ulrike</creator><creatorcontrib>Gish, Robert G. ; Basit, Syed Abdul ; Ryan, John ; Dawood, Altaf ; Protzer, Ulrike</creatorcontrib><description>Purpose of Review It is crucial for clinicians to understand the need to screen for hepatitis B core antigen (anti-HBc status), proper interpretation of HBV biomarkers, and that “anti-HBc only” indicates HBV exposure, lifelong persistence of cccDNA with incomplete infection control, and potential risk for reactivation. Findings Many common misconceptions exist, including that tests for anti-HBc have high false-positive rates, that patients with anti-HBc alone or occult hepatitis B may profit from “vaccine boosting” to achieve immune control of HBV, and that anti-HBc(+)/anti-HBs(+) patients have cleared HBV when they have actually achieved immune control, while HBV persists in some hepatocytes and can reactivate. Summary This review breaks down several common misconceptions regarding anti-HBc with the most recent evidence. In addition, current best strategies for anti-HBc testing and interpretation are reviewed and summarized.</description><identifier>ISSN: 2195-9595</identifier><identifier>EISSN: 2195-9595</identifier><identifier>DOI: 10.1007/s11901-020-00522-0</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Hepatitis B (JK Lim ; Hepatology ; Medicine ; Medicine &amp; Public Health ; Section Editor ; Topical Collection on Hepatitis B</subject><ispartof>Current hepatology reports, 2020-09, Vol.19 (3), p.254-265</ispartof><rights>The Author(s) 2020. corrected publication 2020</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2500-2094ad901b956685bfcb2b828027227d559c212f7e3eba75c810c4face7b34dd3</citedby><cites>FETCH-LOGICAL-c2500-2094ad901b956685bfcb2b828027227d559c212f7e3eba75c810c4face7b34dd3</cites><orcidid>0000-0001-6306-3189</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Gish, Robert G.</creatorcontrib><creatorcontrib>Basit, Syed Abdul</creatorcontrib><creatorcontrib>Ryan, John</creatorcontrib><creatorcontrib>Dawood, Altaf</creatorcontrib><creatorcontrib>Protzer, Ulrike</creatorcontrib><title>Hepatitis B Core Antibody: Role in Clinical Practice in 2020</title><title>Current hepatology reports</title><addtitle>Curr Hepatology Rep</addtitle><description>Purpose of Review It is crucial for clinicians to understand the need to screen for hepatitis B core antigen (anti-HBc status), proper interpretation of HBV biomarkers, and that “anti-HBc only” indicates HBV exposure, lifelong persistence of cccDNA with incomplete infection control, and potential risk for reactivation. Findings Many common misconceptions exist, including that tests for anti-HBc have high false-positive rates, that patients with anti-HBc alone or occult hepatitis B may profit from “vaccine boosting” to achieve immune control of HBV, and that anti-HBc(+)/anti-HBs(+) patients have cleared HBV when they have actually achieved immune control, while HBV persists in some hepatocytes and can reactivate. Summary This review breaks down several common misconceptions regarding anti-HBc with the most recent evidence. In addition, current best strategies for anti-HBc testing and interpretation are reviewed and summarized.</description><subject>Hepatitis B (JK Lim</subject><subject>Hepatology</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Section Editor</subject><subject>Topical Collection on Hepatitis B</subject><issn>2195-9595</issn><issn>2195-9595</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kMFKAzEQhoMoWGpfwFNeIDqZ3TQb8VIXtUKhRfQckmxWUtbdkqyHvr2x68GTpxmG-WZ-PkKuOdxwAHmbOFfAGSAwAIHI4IzMkCvBlFDi_E9_SRYp7QGAo5AS-Yzcr_3BjGEMiT7Qeoiervox2KE53tHXofM09LTuQh-c6eguGjcGdxpifndFLlrTJb_4rXPy_vT4Vq_ZZvv8Uq82zKEAYAiqNE2OaJVYLithW2fRVlgBSkTZCKEccmylL7w1UriKgytb47y0Rdk0xZzgdNfFIaXoW32I4dPEo-agfxToSYHOmfRJgYYMFROU8nL_4aPeD1-xzzn_o74BJrBbpQ</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Gish, Robert G.</creator><creator>Basit, Syed Abdul</creator><creator>Ryan, John</creator><creator>Dawood, Altaf</creator><creator>Protzer, Ulrike</creator><general>Springer US</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0001-6306-3189</orcidid></search><sort><creationdate>20200901</creationdate><title>Hepatitis B Core Antibody: Role in Clinical Practice in 2020</title><author>Gish, Robert G. ; Basit, Syed Abdul ; Ryan, John ; Dawood, Altaf ; Protzer, Ulrike</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2500-2094ad901b956685bfcb2b828027227d559c212f7e3eba75c810c4face7b34dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Hepatitis B (JK Lim</topic><topic>Hepatology</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Section Editor</topic><topic>Topical Collection on Hepatitis B</topic><toplevel>online_resources</toplevel><creatorcontrib>Gish, Robert G.</creatorcontrib><creatorcontrib>Basit, Syed Abdul</creatorcontrib><creatorcontrib>Ryan, John</creatorcontrib><creatorcontrib>Dawood, Altaf</creatorcontrib><creatorcontrib>Protzer, Ulrike</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>CrossRef</collection><jtitle>Current hepatology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gish, Robert G.</au><au>Basit, Syed Abdul</au><au>Ryan, John</au><au>Dawood, Altaf</au><au>Protzer, Ulrike</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatitis B Core Antibody: Role in Clinical Practice in 2020</atitle><jtitle>Current hepatology reports</jtitle><stitle>Curr Hepatology Rep</stitle><date>2020-09-01</date><risdate>2020</risdate><volume>19</volume><issue>3</issue><spage>254</spage><epage>265</epage><pages>254-265</pages><issn>2195-9595</issn><eissn>2195-9595</eissn><abstract>Purpose of Review It is crucial for clinicians to understand the need to screen for hepatitis B core antigen (anti-HBc status), proper interpretation of HBV biomarkers, and that “anti-HBc only” indicates HBV exposure, lifelong persistence of cccDNA with incomplete infection control, and potential risk for reactivation. Findings Many common misconceptions exist, including that tests for anti-HBc have high false-positive rates, that patients with anti-HBc alone or occult hepatitis B may profit from “vaccine boosting” to achieve immune control of HBV, and that anti-HBc(+)/anti-HBs(+) patients have cleared HBV when they have actually achieved immune control, while HBV persists in some hepatocytes and can reactivate. Summary This review breaks down several common misconceptions regarding anti-HBc with the most recent evidence. In addition, current best strategies for anti-HBc testing and interpretation are reviewed and summarized.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s11901-020-00522-0</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-6306-3189</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2195-9595
ispartof Current hepatology reports, 2020-09, Vol.19 (3), p.254-265
issn 2195-9595
2195-9595
language eng
recordid cdi_crossref_primary_10_1007_s11901_020_00522_0
source Springer Nature
subjects Hepatitis B (JK Lim
Hepatology
Medicine
Medicine & Public Health
Section Editor
Topical Collection on Hepatitis B
title Hepatitis B Core Antibody: Role in Clinical Practice in 2020
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T17%3A45%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref_sprin&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatitis%20B%20Core%20Antibody:%20Role%20in%20Clinical%20Practice%20in%202020&rft.jtitle=Current%20hepatology%20reports&rft.au=Gish,%20Robert%20G.&rft.date=2020-09-01&rft.volume=19&rft.issue=3&rft.spage=254&rft.epage=265&rft.pages=254-265&rft.issn=2195-9595&rft.eissn=2195-9595&rft_id=info:doi/10.1007/s11901-020-00522-0&rft_dat=%3Ccrossref_sprin%3E10_1007_s11901_020_00522_0%3C/crossref_sprin%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2500-2094ad901b956685bfcb2b828027227d559c212f7e3eba75c810c4face7b34dd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true